Lifeboat Foundation

New research on Parkinson and holds additional insights in cell & neuro technology.

Autophagy functions as a main route for the degradation of superfluous and damaged constituents of the cytoplasm. Defects in autophagy are implicated in the development of various age-dependent degenerative disorders such as cancer, neurodegeneration and tissue atrophy, and in accelerated aging. To promote basal levels of the process in pathological settings, we previously screened a small molecule library for novel autophagy-enhancing factors that inhibit the myotubularin-related phosphatase MTMR14/Jumpy, a negative regulator of autophagic membrane formation. Here we identify AUTEN-99 (autophagy enhancer-99), which activates autophagy in cell cultures and animal models. AUTEN-99 appears to effectively penetrate through the blood-brain barrier, and impedes the progression of neurodegenerative symptoms in Drosophila models of Parkinson’s and Huntington’s diseases. Furthermore, the molecule increases the survival of isolated neurons under normal and oxidative stress-induced conditions. Thus, AUTEN-99 serves as a potent neuroprotective drug candidate for preventing and treating diverse neurodegenerative pathologies, and may promote healthy aging.

Your life achievements deserve better motivators than death.

Some time ago, I bumped into a short excerpt of a video interview with Neil deGrasse Tyson and Larry King. After I watched it, I was sadly surprised by what deGrasse Tyson said. Before you read further, you should take a minute to watch the interview below. If you can’t see the video or can’t be bothered to watch it, you’ll find a transcript right below it.

NdGT: If you could live forever, would you?

Continue reading “Doing the right things for the wrong reasons” »

Another SENS therapy moving closer to the clinic this time LysoSENS gets the spotlight thanks to Ichor and their new therapy for age-related blindness.

Yet another SENS repair therapy moving into clinical testing, this time age-related blindness is the focus thanks to Ichor Therapeutics.

Wish he & a couple of others would join this ranks that others are on which makes way more sense plus benefits the masses tremendously. Musk needs to join others in their work to enhance humans via Quantum Biosystems as this work is already showing signs of success across multiple areas such as anti-aging, disease elimination, intelligence & communications, security, reduction in costs of healthcare & social programs, advancements in new creative innovations in technology & medicine, new industry new growth/ economic expansion, elimination of starvation, etc.

How can humans stay relevant in an age of artificial intelligence? Elon Musk thinks cyborgs are the answer.

The Tesla and SpaceX CEO discussed the need for a “merger of biological intelligence and digital intelligence” during a talk on Monday at the World Government Summit in Dubai, CNBC reported.

Continue reading “Elon Musk sees critical role for cyborgs” »

This article does try to highlight what and where we are going with the merge of bio and technology. However, what has been shown to date is all very invasive as Quantum Biology has remained a gap in this development work until recently. Thanks to DARPA and others in the private sector who are working on technologies that leverages Quantum Biology principles to develop new integrated Biosystem technologies; we will see amazing work in cell circuitry and connectivity in areas of bio-security, BMI, prosthetics, immunology, anti-disease, reverse aging, etc.

These might sound like outlandish predictions, but DARPA’s Sanchez said it’s not as crazy as it might have sounded several years ago.

“Advancement of A.I. is making machines more powerful in the way they can understand everything from scientific papers to interpreting them and helping us solve big problems,” said Sanchez. “Another aspect to consider is our society [is] embracing things like wearables that… allow algorithms to analyze our physiology. Great examples of that are being able to monitor your sleep patterns and provide feedback on if you should change the time you go to bed or wake up in the morning.”

Continue reading “DARPA: We’re on cusp of merging human and machine” »

Ageing as a disease, take 2: Things I got wrong.

My previous post was somewhat confusing even to myself. To be completely frank, I think it was a little bit of a fuck-up. Several people have commented about it, for example on Reddit or Facebook, pointing out among the rest that whether or not ageing is a disease isn’t just semantics and it isn’t pointless. (To the people commenting on Facebook, I’d like to say that I’m sorry I didn’t reply to your comments, but for some reason I was stuck as ‘Rejuvenaction’ on those posts, and Pages don’t seem to be allowed to comment on group posts. I tried to switch to my personal account to no avail. I figured out a workaround, but at this point it’s a bit too late.)

What I meant to say is that arguing whether or not ageing is a medical condition is far less important than treating its root causes, and as long as we focused on this task, we could postpone the debate to a later time. The finer points of establishing if ageing fits the definition of ‘disease’ to the letter would waste precious time we could spend saving lives instead; we should definitely not wait until the issue has been settled before we start developing rejuvenation biotechnologies. (And we are not waiting at all, luckily.) However, classifying ageing as a disease is very important and not at all pointless, as Reason of FA! explained in this post. In a nutshell, if the ageing processes that lead to age-related diseases were considered pathological, research on how to interfere with them would likely receive more funding, and drugs that target ageing itself could be approved by the FDA.

The effects of a rapidly aging population have a number of serious economic and social implications.

What a rapidly aging populaton means to the economy and the workforce and why biotechnology is the answer.

#aging #economy

Continue reading “4 Main Economic Implications Of An Aging Population, And How Life Extension Technologies Could Solve Them” »

Let’s debate whether ageing is a disease *after* the diseases of old age are eliminated, shall we?

Whether or not ageing ought to be considered a disease is still matter of controversy, both among experts and laypeople. Particularly, the latter tend to turn up their noses at the thought of ageing being pathological and not ‘normal’, especially if they’re outside the life-extension/rejuvenation community. Clearly, they ignore the fact that ‘normal’ and ‘pathological’ aren’t mutually exclusive at all. It’s perfectly normal to suffer from hear loss in old age; notwithstanding, it is out of the question that hear loss is a pathology and we have developed several ways to make up for it. It presently can’t be cured, because like all age-related diseases, it can only get worse as long as the age-related damage that causes it keeps accumulating.

In my humble opinion of quasi-layperson (I’m nowhere near being an expert, but I do think I know about ageing more than your average Joe), whether or not ageing is a disease is merely a matter of semantics, depending largely on what we want to label as ‘ageing’—not to mention how we define ‘disease’.

If we say that ‘ageing’ is the set of age-related pathologies that affect a given person, then ageing isn’t a disease any more than a box of crayons is itself a crayon. Nonetheless, if you have a box of crayons then you have a bunch of crayons; if you have ageing as we defined it, then you have a bunch of diseases, and the grand total of your ailments doesn’t change whether you consider ageing as a disease as well or not. Quite frankly, I’d pick the box of crayons over ageing any time.

Continue reading “Health before semantics” »

Summary:

• Many recent advances in artificial intelligence and aging biomarkers that transpired since 2013 are converging
• Gachon University and Gil Medical Center are at the forefront of aging research in Korea
• Aging research is gaining credibility in the pharmaceutical industry and healthcare in general
• Insilico Medicine and Gachon University and Gil Medical Center have partnered to collaboratively develop biomarkers and interventions

Friday, 3rd of February, 2017, Baltimore, MD — Insilico Medicine today announced that it signed a Memorandum of Understanding (MOU) and started the first collaborative research project with one of the largest research and medical networks, Gachon University and Gil Medical Center. The intent of the long-term collaboration is to develop artificially intelligent multimodal biomarkers of aging and health status as well as interventions intended to slow down or even reverse the processes leading to the age-related loss of function.